source
- STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADAYou're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference.STAT · 2mo ago↗ source
- #ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effectsBoehringer Ingelheim’s obesity asset survodutide, which it licensed from Zealand Pharma, has shown high rates of discontinuations in its Phase 3 obesity study. In April, data from the SYNCHRONIZE-1…Endpoints · 2mo ago↗ source
- STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drugBoehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.STAT